NRC FORM 374	PAGEOFPAGES					
U.S. NUCLEAR REGULAT						
MATERIALS						
Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 39, 40, and 70, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.						
Licensee	In accordance with letter dated					
	November 18, 2009,					
1. Adams Memorial Hospital	3. License number 13-26133-01 is amended in its entirety as follows:					
2. 1100 Mercer Avenue	4. Expiration date March 31, 2015					
Decatur, IN 46733	5. Docket No. 030-31518					
	Reference No.					
<ol> <li>Byproduct, source, and/or special</li> <li>Chemical and/or ph nuclear material</li> </ol>	eysical form 8. Maximum amount that licensee may possess at any one time under this license					
A. Any byproduct material A. Any permitted by 10 CFR 35.100	A. As needed					
B. Any byproduct material B. Any permitted by 10 CFR 35.200	B. As needed					
C. Any byproduct material C. Any permitted by 10 CFR 35.300	C. Not to exceed 1 curie					
9. Authorized Use:						
A. Any uptake, dilution and excretion study permitte	ed by 10 CFR 35.100.					
B. Any imaging and localization study permitted by	10 CFR 35.200.					
C. Any diagnostic study or therapy procedure perm	itted by 10 CFR 35.300.					
CONDITION	<u>S</u>					
<ol> <li>Licensed material shall be used only at the licensee's facilities located at 1100 Mercer Avenue, Decatur, Indiana.</li> </ol>						
11. Radiation Safety Officer: John Pasalich, M.D.						
T. Radiation Safety Officer. John Fasalich, W.D.						

NRC FORM 374A U.S. NUCLEAR REGULATORY COMMISSION			U.S. NUCLEAR REGULATORY CO	PAGE 2 of 4 PAGES					
MATERIALS LICENSE				License Number 13-26133-01 Docket or Reference Number 030-31518					
		SUPPLE	EMENTARY SHEET		Amendment No. 05				
					Amendment No. 05				
_									
12.	Lice	ensed material is o	only authorized for use by, or	under th	e supervision of:				
	A.	Individuals permit	tted to work as an authorized	d user in	accordance with 10 CFR 35.13 and 35.14.				
	В.	The following indi	lividuals are authorized users	s for mec	lical use as indicated:				
		Authorized Users		Materi	al and Use				
			-						
		John Rock, M.D.			R 35.100, 35.200 and iodine-131 for diagnostic s permitted by 35.300.				
		Richard Stephens	s, Jr., M.D.		R 35.100, 35.200 and iodine-131 for diagnostic permitted by 35.300.				
		John Pasalich, M	I.D.	10 CFF	R 35.100, 35.200 and 35.300.				
		Stephen R. Phillip	ρ, M.D.	10 CFF	R 35.100, 35.200 and 35.300.				
		Marc Thomas, M.	.D.	10 CFF	R 35.100, 35.200 and 35.300.				
		James C. Wehrer	nberg, M.D.		R 35.100, 35.200 and iodine-131 for diagnostic permitted by 35.300.				
		Diane D. Daly, M.	.D.	10 CFF	R 35.100, 35.200 and 35.300.				
		Frederick N. Vand	deman, M.D.		R 35.100, 35.200 and 35.300 (excluding iodine- thyroid carcinoma).				
		James A. Arata, N	M.D.	10 CFF	R 35.100, 35.200 and 35.300.				
		Joseph R. Decam	וף, M.D.		R 35.100, 35.200 and iodine-131 (for diagnostic permitted by 35.300 and hyperthyroidism).				
		John L. Bormann,	, M.D.	10 CFF	R 35.100, 35.200 and 35.300.				
		Michael E. Parker	r, M.D.	10 CFR	R 35.100, 35.200 and 35.300.				
		Michael W. Tanks	sley, M.D.		R 35.100, 35.200 and 35.300 (excluding iodine- thyroid carcinoma).				
		John R. Kim, M.D	ı.		8 35.100, 35.200 and 35.300 (excluding iodine- thyroid carcinoma).				
		David B. Janizek,	M.D.	10 CFR	8 35.100, 35.200 and 35.300.				
		Pamela Lee Stran	ıge, M.D.	10 CFR	35.100, 35.200 and 35.300.				
		Christine Anne Tre	emper, M.D.		35.100, 35.200 and iodine-131 for diagnostic permitted by 35.300 and hyperthyroidism).				

NRC FORM 374A	U.S. NUCLEAR REGULATORY COM	MISSION	PAGE 3 of 4 PAGES
			License Number 13-26133-01
MATERIALS LICENSE SUPPLEMENTARY SHEET		Docket or Reference Number 030-31518	
			Amendment No. 05
1 <del>9</del>			
Authoriz	ed Users	Materia	Il and Use
Randall	J. Phillips, M.D.	10 CFF	R 35.100, 35.200 and 35.300.
Richard	W. Sibley, M.D.	10 CFF	R 35.100, 35.200 and 35.300.
Dakshes	sh S. Patel, M.D.		R 35.100, 35.200 and iodine-131 for diagnostic permitted by 35.300.
Christop	her M. Kowalski, M.D.		R 35.100, 35.200 and iodine-131 for diagnostic permitted by 35.300.
Brett A. I	Hagedorn, M.D.	10 CFF	R 35.100, 35.200 and 35.300.
Andre B.	. Stovall, M.D.	10 CFF	R 35.100, 35.200 and 35.300.
Gina W.	Hook, M.D.		8 35.100, 35.200 and iodine-131 for diagnostic permitted by 35.300.
Eric V. H	leatwole, M.D.	10 CFF	35.100 and 35.200.
Shilpa Ka	ashyap, M.D.	10 CFR	35.100 and 35.200.
Ralph W	. Richardson, M.D.	10 CFR	35.100 and 35.200.
Daniel B	Branam, M.D.	10 CFR	35.100 and 35.200.

- 13. In addition to the possession limits in Item 8, the licensee shall further restrict the possession of licensed material to quantities below the minimum limit specified in 10 CFR 30.35(d) for establishing decommissioning financial assurance.
- 14. The licensee is authorized to transport licensed material in accordance with the provisions of 10 CFR Part 71, "Packaging and Transportation of Radioactive Material."

NRC FORM 374A	U.S. NUCLEAR REGULATORY COMMISSION		PAGE	4	of	4 PAGES	
		License Number 13-26133-01					
MATERIALS LICENSE SUPPLEMENTARY SHEET	Docket or Reference Number 030-31518						
		Amendment No. 05					-
					and the second se		

15. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below. This license condition applies only to those procedures that are required to be submitted in accordance with the regulations. Additionally, this license condition does not limit the licensee's ability to make changes to the radiation protection program as provided for in 10 CFR 35.26. The U.S. Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence are more restrictive than the regulations.

A. Application dated January 21, 2005.

## FOR THE U.S. NUCLEAR REGULATORY COMMISSION

Date FEB 1 2 2010

by L. Semmons By

Toye L. Simmons<sup>1</sup> Materials Licensing Branch Region III